Clinical trial · Observational
COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies
Multicenter, Observational Study of Anti-Sars-Cov2 Vaccine Efficacy in Patients With Malignant Pathologies Treated in the University Hospitals of AP-HP. Nord
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addition to more classic factors such as age, general condition and possibly the type of vaccine used. There are very little data on the efficacy and immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with malignant disease in the active phase of treatment. This multicenter observational study aims to assess the efficacy and the immunogenicity of anti-Sars-CoV-2 vaccines in the cohort of patients treated for malignant pathology (solid or hematological tumors) at Saint Louis Hospital and in thoracic oncology patients at Bichat Hospital.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Treatment-Related | Malignant Neoplasm | ALIAS | 0.85 |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Thoracic Cancer | Malignant Thoracic Neoplasm | ALIAS | 0.90 |
| Vaccine Response Impaired | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Patients with malignant disease undergoing chemotherapy
- description
- Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
- interventionNames
- Other: Data collection
- label
- Patients with malignant disease undergoing chemotherapy + immunotherapy
- description
- Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
- interventionNames
- Other: Data collection
- label
- Patients with malignant disease undergoing immunotherapy
- description
- Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with malignant disease undergoing treatment at Saint Louis Hospital or Bichat Hospital (for chest cancer) * with chemotherapy * with chemotherapy + Immunotherapy * with immunotherapy * with targeted therapies * with radiotherapy * in the event of radiation pneumonitis after radiotherapy for lung cancers * after pneumonectomy for lung cancer * Patient informed and having expressed their non-opposition to participating in this research Exclusion Criteria: * Patient with a contraindication to Sars-Cov2 vaccination
References
Publications (0)
Data not yet available